Safety, pharmacokinetics, and antiretroviral activity of intravenous 9- [2-(R)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 9, 1998, Pages 2380-2384

  Deeks, Steven G ^a,d   Barditch Crovo, Patricia ^b   Lietman, Paul S ^b   Hwang, Frances ^c   Cundy, Kenneth C ^c   Rooney, James F ^c   Hellmann, Nicholas S ^c,e   Safrin, Sharon ^c   Kahn, James O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GILEAD SCIENCES   (United States)

^d SAN FRANCISCO GENERAL HOSPITAL   (United States)

^e MONOGRAM BIOSCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 [2 (PHOSPHOMETHOXY)PROPYL]ADENINE; ANTIRETROVIRUS AGENT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS DETECTION;

EID: 0031710248     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.9.2380     Document Type: Article

References (14)

1. Arimilli, M. N., C. U. Kim, J. Dougherty, A. Mulato, R. Oliyai, J. P. Shaw, K. U. Crundy, and N. Bischofberger. 1997. Synthesis, in vitro biological evaluation and oral bioavailability of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) prodrugs. Antivir. Chem. Chemother. 8:557-564.
2. Balzarini, J., C. Perno, D. Schols, and E. De Clercq. 1991. Activity of acyclic phosphonate analogues against human immunodeficiency virus in monocytes/macrophages and peripheral blood lymphocytes. Biochem. Biophys. Res. Commun. 178:329-335.
3. Balzarini, J., H. Zhang, P. Herdewijn, D. Johns, and E. De Clercq. 1991. Intracellular metabolism and mechanism of antiretrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc. Natl. Acad. Sci. USA 88:1499-1503.
4. Cherrington, J. M., R. Chandok, A. S. Mulato, P. D. Lamy, H. Mitsuya, and M. Wainberg. 1997. In vitro selection and characterization of HIV-1 variants with reduced susceptibility to PMPA, abstr. I-113, p. 264. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada.
5. Danner, S. A., A. Carr, J. M. Leonard, L. M. Lehman, F. Gudiol, J. Gonzales, A. Raventos, R. Rubio, E. Bouza, V. Pintado, A. Gil Aguado, J. Garci de Lomas, R. Delgado, J. C. C. Borleffs, A. Hsu, J. M. Valdes, C. A. B. Boucher, and D. A. Cooper. 1995. A short term study of the safety, pharmacokinetics and efficacy of ritonavir, an inhibitor of HIV-1 protease. N. Engl. J. Med. 333:1528-1533.
6. Deeks, S. G., P. Barditch-Crovo, P. S. Lietman, A. Collier, S. Safrin, R. Coleman, K. C. Cundy, and J. O. Kahn. 1998. The safety and efficacy of PMPA prodrug monotherapy: preliminary results of a phase I/II dose-escalation study, abstr. LB8. In Program and abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, Ill.
7. Gao, W. Y., T. Shirasaka, D. G. Johns, S. Broder, and H. Mitsutya. 1993. Differential phosphorylation of azidothymidine, dideoxycytidine and dideoxyinosine in resting and activated peripheral blood nuclear cells. J. Clin. Investig. 91:2326-2333.
8. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
9. Katzenstein, D. A., S. M. Hammer, M. D. Hughes, H. Gundacker, J. B. Jackson, S. Fiscus, S. Rasheed, T. Elbeik, R. Reichman, A. Japour, T. C. Merigan, and M. S. Hirsch. 1996. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N. Engl. J. Med. 335:1091-1098.
10. Poli, G., J. M. Orenstein, A. Kinter, T. M. Folks, and A. S. Fauci. 1989. Interferon-a but not AZT suppresses HIV expression in chronically infected cell lines. Science 244:575-577.
11. Robbins, B. L., R. V. Srinivas, C. Kim, N. Bischofberger, and A. Fridland. 1998. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA). bis(isopropyloxymethylcarbonyl) PMPA. Antimicrob. Agents Chemother. 42:612-617.
12. Tsai, C.-C., K. E. Follis, T. W. Beck, A. Sabo, N. Bischofberger, and P. J. Dailey. Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy in chronic SIV infection in macaques. AIDS Res. Hum. Retroviruses 13:707-711.
13. Tsai, C.-C., K. Follis, A. Sabo, T. Beck, R. Grant, N. Bischofberger, R. Benveniste, and R. Black. 1995. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 270:1197-1199.
14. van Rompay, K. K. A., J. M. Cherrington, M. Marthas, C. J. Berardi, A. S. Mulato, A. Spinner, R. P. Tarara, D. R. Canfield, S. Telm, N. Bischofberger, and N. Pedersen. 1996. 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob. Agents Chemother. 40:2586-2591.